|
GB9501178D0
(en)
*
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
|
EP0874631B1
(en)
*
|
1996-01-19 |
2003-11-19 |
Glaxo Group Limited |
Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
|
|
IT1283447B1
(it)
*
|
1996-07-18 |
1998-04-21 |
Ind Chimica Srl |
Processo di preparazione del valaciclovir e relativi intermedi
|
|
CN1250449A
(zh)
*
|
1997-01-17 |
2000-04-12 |
味之素株式会社 |
新型z-伐昔洛韦结晶
|
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
|
RS55023B1
(sr)
*
|
2001-02-24 |
2016-11-30 |
Boehringer Ingelheim Pharma |
Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
|
|
KR100774271B1
(ko)
*
|
2001-09-07 |
2007-11-08 |
테바 파마슈티컬 인더스트리즈 리미티드 |
발라사이클로비르 염산염의 결정질 형태
|
|
AU2002348022B2
(en)
*
|
2001-11-05 |
2006-06-15 |
Glaxo Group Limited |
Anhydrous crystal form of valaciclovir hydrochloride
|
|
PL371732A1
(en)
*
|
2001-11-14 |
2005-06-27 |
Teva Pharmaceutical Industries Ltd. |
Synthesis and purification of valacyclovir
|
|
AU2003240213A1
(en)
*
|
2002-06-24 |
2004-01-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
|
AU2003277433A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Teva Pharmaceutical Industries Ltd. |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
|
EP1575953A1
(en)
*
|
2002-12-09 |
2005-09-21 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
|
AU2003232719A1
(en)
*
|
2003-05-30 |
2005-01-21 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
|
US20050085491A1
(en)
*
|
2003-06-02 |
2005-04-21 |
Igor Lifshitz |
Novel crystalline forms of valacyclovir hydrochloride
|
|
KR20060117355A
(ko)
*
|
2004-01-21 |
2006-11-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
발라시클로버 염산염의 제조 방법
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CA2572268A1
(en)
*
|
2004-06-30 |
2006-02-02 |
Teva Pharmaceutical Industries Ltd. |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
|
EP1891071B1
(en)
*
|
2005-05-25 |
2012-02-22 |
Eli Lilly And Company |
Cyclopropanecarboxylate esters of acyclovir
|
|
EP1746098A1
(en)
*
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir polymorphs and a process for the preparation thereof
|
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
CN1903854B
(zh)
*
|
2006-08-09 |
2012-05-23 |
丽珠医药集团股份有限公司 |
一种合成盐酸伐昔洛韦的方法
|
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
|
GB0710277D0
(en)
*
|
2007-05-30 |
2007-07-11 |
Univ Birmingham |
Use of antivirals in the treatment of medical disorders
|
|
KR101610005B1
(ko)
*
|
2007-08-17 |
2016-04-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
|
|
WO2009031576A1
(ja)
*
|
2007-09-03 |
2009-03-12 |
Ajinomoto Co., Inc. |
バラシクロビル塩酸塩結晶の製造方法
|
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
|
PE20140960A1
(es)
*
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
AU2009281122C1
(en)
*
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
NZ592924A
(en)
|
2008-12-23 |
2014-05-30 |
Boehringer Ingelheim Int |
Salt forms of a xanthine derivative
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
US9186392B2
(en)
|
2010-05-05 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
|
WO2011158252A1
(en)
|
2010-06-15 |
2011-12-22 |
Matrix Laboratories Ltd |
Process for the preparation of valacyclovir hydrochloride polymorphic form ii
|
|
EP3725325B1
(en)
|
2010-06-24 |
2023-05-31 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
|
CN103781788B
(zh)
|
2011-07-15 |
2016-08-17 |
勃林格殷格翰国际有限公司 |
经取代的喹唑啉、其制备及其在药物组合物中的用途
|
|
US20140296520A1
(en)
*
|
2011-11-25 |
2014-10-02 |
Piramal Enterprises Limited |
Process for the preparation of valacyclovir hydrochloride
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
ES2929025T3
(es)
|
2012-05-14 |
2022-11-24 |
Boehringer Ingelheim Int |
Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
|
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
|
KR102391564B1
(ko)
|
2016-06-10 |
2022-04-29 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴 및 메트포르민의 병용물
|
|
CN110437231B
(zh)
*
|
2019-09-04 |
2022-04-29 |
上药康丽(常州)药业有限公司 |
一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
|
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|